1. At a Glance
PGHH is the FMCG stock that makes retail investors whisper in awe and sneeze at its valuation. With a market cap of ₹44,302 Cr and CMP ₹13,648, the stock trades at a lofty P/E of 53.5. In FY24, sales stood at ₹4,311 Cr, net profit ₹829 Cr, and OPM an elite 26%. Dividend payout? 89%—basically, P&G India is an ATM for shareholders. Whisper dominates with 50%+ market share in sanitary pads, Vicks commands over 50% in cough/cold, and Old Spice… well, at least makes Instagram reels smell nicer. But sales growth crawled at 2.5%, even as profit growth hit 22.8% TTM. Returns? 1-year: -17%, 3-year: flat, 5-year: +7%. Basically, Whisper pads are growing faster than the company.
2. Introduction
PGHH is that posh kid in your colony—rich, premium, always immaculately dressed, but a bit slow at the race. Incorporated as Richardson Hindustan in 1964, acquired by P&G in 1985, it is now India’s premium play in femcare and healthcare. The company doesn’t just sell pads and vaporub, it sells category dominance. Whisper = cultural synonym for sanitary pads. Vicks = childhood memory of every Indian mom rubbing balm on your chest during flu. Old Spice = nostalgia for your dad’s shaving cabinet.
But here’s the twist: revenue growth is slower than the line at an SBI branch, while profitability and ROE are shooting through the roof—ROE at 75.7%, ROCE at a comical 104%. Translation: This is a cash-spewing FMCG god, but it refuses to scale like peers Dabur, Godrej, or Colgate. Investors pay 53× earnings because they’re betting “monopoly margins” will outshine sluggish sales. The stock, however, has underperformed badly—down 17% in a year. Which begs the question: are you buying Whisper’s whisper, Vicks’ vapor, or just P&G’s brand halo?
3. Business Model – WTF Do They Even Do?
Think of PGHH as a two-engine jet with a small afterburner:
- Whisper (70% revenue): Ultra Clean, Ultra Softs, Bindazzz Nights, Daily Liners, and now Period Panties. Basically, Whisper doesn’t whisper—it shouts market dominance with 50%+ share. Double-digit growth expected in femcare for the next 3 years.
- Vicks (30% revenue): VapoRub, Inhaler, Throat Drops, Action 500
